Joseph Yanity

Neonatology fellowship-trained physician assistant with extensive experience in Level II-IV NICUs and neonatal transport, skilled in managing complex cases and ensuring optimal care for newborns. Proficient in neonatal resuscitation and advanced procedural skills, contributing to improved patient outcomes. Committed to staying current with the latest developments in neonatal care and fostering collaborative environments with healthcare teams to deliver exceptional service.

• 2007- American Academy of Physician Assistants – Fellow
• 2005-2006 Washington Academy of Physician Assistants – Board Member/Student Representative
• 2010-2017 American Urological Association-Allied Professional

• 10/2007-current

National Commission on Certification of Physician Assistants (#1080000)

• 10/2007-current

Washington State Department of Health Physician Assistant License (credential # PA 10005287)

• 6/2017-current

California Physician Assistant License #54584

• 2/24/2017 (Current) Pediatric Advanced Life Support
• 2/27/2017 (Current) Neonatal Resuscitation Program Provider Course

2023 & 2024 Nominee- Elizabeth Thomas Award for Professionalism and Integrity, Seattle Children’s Hospital

Seattle Met’s 2017 Top Doctors, Nurse Practitioners and Physician Assistants

University of Washington Urology Staff Member of the Year 2012-2013

Named contributor to: Robinson RP, Five-Year Follow-up of Primary Optetrak Posterior Stabilized Total Knee Arthroplasties in Osteoarthritis. J. Arth 2005 Vol 20, No 7, pg 927-931.

• 1) Sub Investigator: BRI# IRB08100 Investigator Initiated. Effects of Perioperative Belladonna and Opium Suppositories on Postoperative Pain and Morphine Consumption on Patients after Robotic Assisted Laparoscopic Radical Prostatectomy (2008 - 2009)
• 2) Sub Investigator: BRI # IRB08078 The Pacific Northwest Prostate Cancer SPORE NCI grant. Phase III Study of Neoadjuvant IMC-A12 combined with Androgen Deprivation Prior to Prostatectomy (2008 – present)
• 3) Sub Investigator: BRI # IRB09033 Dendreon Corporation. An Open-Label Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (2009-present)
• 4) Sub Investigator: BRI #IRB08128 – Dendreon P07-1: An Open Label, Phase 2 Trial of Immunotherapy with Sipuleucel-T (Provenge) As Neoadjuvant Treatment in Men with Localized Prostate Cancer 2009- present
• 5) Sub Investigator: BRI#IRB09044 - Dendreon P07-2: A Randomized, Multicenter, Single Blind Study in Men with Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured with Different Concentrations of PA2024 Antigen 2009- present
• 6) Sub Investigator: BRI #IRB11082- Dendreon P10-1: An Open-Label, Multicenter Study of Sipuleucel-T in Patients Previously Treated with Sipuleucel-T on Dendreon Study P-11 2011- present
• 7) Sub Investigator: BRI #IRB11110 - Dendreon P10-2: A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Non-Metastatic Prostate Cancer with a Rising Serum Prostate Specific Antigen after Primary Therapy 2011 present
• 8) Sub Investigator: BRI #IRB11155 -Dendreon P11-3: A Randomized, Open-Label, Phase 2 Trial of Sipuleucel-T with Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men with Metastatic Castrate Resistant Prostate Cancer 2011- present
• 9) Sub Investigator: BRI #IRB11041 - Dendreon N10-1: A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma 2011- present